T1	Participants 48 74	symptomatic endometriosis:
T2	Participants 143 250	endometriosis patients of a 12-month course of GnRH agonist alone or with one of three "add-back" regimens.
T3	Participants 369 421	All patients had received monthly leuprolide acetate
T4	Participants 678 798	201 patients enrolled in the initial trial, 123 completed at least 280 days of therapy and entered the follow-up period.
T5	Participants 1571 1605	symptomatic endometriosis patients
